EPO Rejects Mirrx Bid to Reinstate Patent Proceedings Ahead of Ruling on Suit with Santaris

Mirrx said the agency's decision may mean it will have to wait as long as two years before it can secure the patent. During that time, it may be unable to secure additional investments needed to stay in business, the company said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.